These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 14652787)
1. Biological markers of the inflammatory phase of multiple sclerosis. Uccelli A; Pedemonte E; Narciso E; Mancardi G Neurol Sci; 2003 Dec; 24 Suppl 5():S271-4. PubMed ID: 14652787 [TBL] [Abstract][Full Text] [Related]
2. Bio-markers of disease activity and response to therapy in multiple sclerosis. Miller A; Glass-Marmor L; Abraham M; Grossman I; Shapiro S; Galboiz Y Clin Neurol Neurosurg; 2004 Jun; 106(3):249-54. PubMed ID: 15177778 [No Abstract] [Full Text] [Related]
4. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Hein Née Maier K; Köhler A; Diem R; Sättler MB; Demmer I; Lange P; Bähr M; Otto M Neurosci Lett; 2008 May; 436(1):72-6. PubMed ID: 18359164 [TBL] [Abstract][Full Text] [Related]
5. Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis. Ukkonen M; Wu K; Reipert B; Dastidar P; Elovaara I Mult Scler; 2007 Jul; 13(6):701-7. PubMed ID: 17613596 [TBL] [Abstract][Full Text] [Related]
7. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Chowdhury SA; Lin J; Sadiq SA Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193 [TBL] [Abstract][Full Text] [Related]
8. Biomarkers for diagnosing and monitoring autoimmune diseases. Prince HE Biomarkers; 2005 Nov; 10 Suppl 1():S44-9. PubMed ID: 16298911 [TBL] [Abstract][Full Text] [Related]
9. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Szczuciński A; Losy J Acta Neurol Scand; 2007 Mar; 115(3):137-46. PubMed ID: 17295707 [TBL] [Abstract][Full Text] [Related]
10. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Moreira MA; Tilbery CP; Monteiro LP; Teixeira MM; Teixeira AL Acta Neurol Scand; 2006 Aug; 114(2):109-13. PubMed ID: 16867033 [TBL] [Abstract][Full Text] [Related]
11. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. Berger T; Reindl M J Neurol Sci; 2007 Aug; 259(1-2):21-6. PubMed ID: 17367811 [TBL] [Abstract][Full Text] [Related]
12. Biological indicators of the neurodegenerative phase of multiple sclerosis. Zaffaroni M Neurol Sci; 2003 Dec; 24 Suppl 5():S279-82. PubMed ID: 14652789 [TBL] [Abstract][Full Text] [Related]
13. Serum markers of vascular inflammation in dyslipemia. Francisco G; Hernández C; Simó R Clin Chim Acta; 2006 Jul; 369(1):1-16. PubMed ID: 16469304 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Truog WE; Ballard PL; Norberg M; Golombek S; Savani RC; Merrill JD; Parton LA; Cnaan A; Luan X; Ballard RA; Pediatrics; 2007 Apr; 119(4):670-8. PubMed ID: 17403837 [TBL] [Abstract][Full Text] [Related]
15. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Iriarte J; de Castro P Neurology; 2002 Apr; 58(7):1134; author reply 1134-5. PubMed ID: 11940715 [No Abstract] [Full Text] [Related]
16. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. Bose CL; Dammann CE; Laughon MM Arch Dis Child Fetal Neonatal Ed; 2008 Nov; 93(6):F455-61. PubMed ID: 18676410 [TBL] [Abstract][Full Text] [Related]